US 12,433,853 B2
Rationally designed lawsone derivatives as antimicrobials against multidrug-resistant Staphylococcus aureus
Min-Ho Kim, Hudson, OH (US); Songping D. Huang, Kent, OH (US); Ronghui Song, Pittsburgh, PA (US); and Bing Yu, Chesterbrook, PA (US)
Assigned to Kent State University, Kent, OH (US)
Appl. No. 17/637,581
Filed by KENT STATE UNIVERSITY, Kent, OH (US)
PCT Filed Aug. 26, 2020, PCT No. PCT/US2020/047943
§ 371(c)(1), (2) Date Feb. 23, 2022,
PCT Pub. No. WO2021/041506, PCT Pub. Date Mar. 4, 2021.
Claims priority of provisional application 62/891,620, filed on Aug. 26, 2019.
Prior Publication US 2022/0273586 A1, Sep. 1, 2022
Int. Cl. A61K 31/122 (2006.01); A61K 31/431 (2006.01); A61K 31/496 (2006.01); A61K 31/5383 (2006.01); A61K 38/14 (2006.01); A61P 31/04 (2006.01); C07C 45/74 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 31/431 (2013.01); A61K 31/496 (2013.01); A61K 31/5383 (2013.01); A61K 38/14 (2013.01); A61P 31/04 (2018.01); C07C 45/74 (2013.01)] 8 Claims
 
1. A method of treating an infected human being and/or animal comprising:
topically administering a composition to said human being and/or animal,
wherein the composition comprises;
one or more compounds having the formula:

OG Complex Work Unit Chemistry
where R, independently, comprises CH2CH3, or (CH2)3CH3, or (CH2)5CH3, or (CH2)7CH3, or any combination thereof,
wherein the composition is capable of inhibiting or reducing the growth of methicillin-sensitive Staphylococcus aureus by at least 1-Log CFU.